Kabuki Syndrome Team Selected to Join Aspire Biosciences’ Partnering Event

Kabuki Syndrome Team Selected to Join Treatment-Focused Networking Event

NEW YORK, April 17, 2023— After submitting a joint application, the Kabuki Syndrome Foundation (KSF) and Kabuki UK were selected to attend the Aspire Biosciences’ Rare Disease Partnering Event! The goal of the event is to find new ways to treat Kabuki syndrome with potential industry partners. Kabuki syndrome represents one of only ten applicants chosen to participate in London in June.

Sally Trewartha, mom to Harry and chairperson of Kabuki UK, and Dr. Clara Tang, Director of Research at KSF, will network with and “speed-date” representatives from pharmaceutical and biotech companies interested in finding treatments for rare diseases that affect the brain and nervous system.

Dr. Tang is responsible for leading the development and execution of research strategy at KSF. Dr. Tang was most recently an Alliance Strategy Manager at Healx, a Cambridge, UK biotech using AI to create novel therapies for rare disease patients. At Healx, she led the development and alliance management of all collaborations with academic and patient group partners. Her past experiences make her an excellent advocate for Kabuki syndrome at this event and beyond. Read more about KSF’s Research Team.

We are so thankful to have this team representing the global Kabuki syndrome community, and look forward to further growing our network to find treatments.